ReviewClinics in chest medicine2026
Pathophysiology and Management of Sepsis-associated Acute Kidney Injury.
Review in Clinics in chest medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and internal validation of a prediction model for early identification of sepsis-associated acute kidney injury based on admission serum biomarkers: a retrospective cohort study.Frontiers in medicine · 2026Article
- Development and validation of a temporal staging-based nomogram for 1-year mortality in sepsis-associated acute kidney injury.Frontiers in cellular and infection microbiology · 2026Article
- Extracellular vesicles mediate immune regulation in acute kidney injury.Frontiers in immunology · 2026Review
- Growth Differentiation Factor 15 (GDF15) Protects Against Sepsis-Associated Acute Kidney Injury via Suppression of TLR4-MyD88-NF-κB Signaling and Ferroptosis.BioFactors (Oxford, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is a complex, life-threatening condition resulting from a dysregulated immune response to infection, leading to organ dysfunction. It is common in critically ill patients and involves multifactorial pathophysiology including inflammation, endothelial damage, mitochondrial dysfunction, and other pathways. SA-AKI increases the need for renal replacement therapy and is linked to poor long-term outcomes. Risk stratification and emerging subphenotyping methods aim to improve diagnosis and treatment. Current management focuses on prevention and supportive care, as no specific pharmacotherapies exist. Ongoing research explores precision medicine approaches and novel interventions to improve outcomes in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.